Dr. Beth Abramson, MD is the Paul Albrechtsen Professor in Cardiac Prevention and Women’s Health in the Division of Cardiology at St. Michael’s Hospital, University of Toronto. She is also an Associate Professor of Medicine at the University of Toronto.
She enjoys educating the public on heart health and is a national spokesperson for the Heart and Stroke Foundation. Her book, Heart Health for Canadians, published in 2013, aims to help people prevent and understand heart disease. In 2015, she was awarded the prestigious Harold N. Segal award of Merit, in recognition of her many contributions to preventing heart disease amongst Canadians. She is a member of the American Society of Preventive Cardiology Women’s working group, and has co-chaired the American College of Cardiology’s Hypertension working group. In 2021, she was invited to become a member of the American College of Cardiology Prevention Council.
In addition, Dr. Abramson is a founding member and inaugural Chair (2018-2020) of the Canadian Women’s Heart Health Alliance Education Working Group, which has created an electronic course and toolkit on Women and Heart Disease for MDs. Dr. Abramson’s has also been involved in the North American Menopause Societys’ (NAMS) awareness efforts.
She currently directs a fellowship in Preventive Cardiology at the University of Toronto and has recently established an academic Cardiometabolic Clinic at St. Michael’s Hospital to close care gaps. Dr. Abramson also works out of the Toronto Cardiac Clinic.
Dr. Guillaume Marquis-Gravel is an interventional cardiologist at the Montreal Heart Institute, and an associate professor at Université de Montréal since 2020. He is a Junior 2 clinical research scholar of the Fonds de la Recherche du Québec – Santé (FRQS). He completed his medical training (M.D.), a Masters in Biomedical Sciences (M.Sc., with Honors), a residency in internal medicine, and a residency in adult cardiology (with Honors) at the Université de Montréal. He then completed a 1-year clinical fellowship in interventional cardiology at Duke University (Durham, NC, United States), followed by a 2-year clinical research fellowship at the Duke Clinical Research Institute.
He is the primary author or co-author of more than 130 peer-reviewed publications, including in the New England Journal of Medicine, JAMA Cardiology, the Journal of the American College of Cardiology, and Circulation, and of 5 book chapters. He is an associate editor of the Canadian Journal of Cardiology. His main research interests revolve around the antithrombotic management of acute and chronic coronary artery disease, prevention of contrast-induced nephropathy after PCI, and development of innovative clinical trial methods. He is the principal investigator of research projects funded by the Canadian Institutes of Health Research (CIHR), the Heart & Stroke Foundation, and the Canadian Heart Function Alliance. He is the co-chair of the 2023 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy.
Dr. Reetesh Bose is a board-certified dermatologist at The Ottawa Hospital and a faculty lecturer in the Division of Dermatology at the University of Ottawa. He completed his dermatology residency training at the University of Ottawa. He is an EDI committee member with the CDA, and Division of Dermatology Lead for EDI with The Ottawa Hospital. With numerous publications, his clinical and research interests include ethnodermatology, medical education, medical, surgical, and cosmetic dermatology. Dr. Bose serves as director of the Ottawa Skin of Colour Dermatology Clinic at The Ottawa Hospital and co-directs the Ottawa-Nunavut Dermatology Program.
Dr. Sonia Anand is a distinguished physician-scientist and global health leader whose work has transformed Canada’s approach to cardiovascular health, health equity, and population health research. She serves as Associate Vice-President of Global Health, She is the founder and inaugural lead of the Mary Heersink School of Global Health and Social Medicine, the Director of the Global-Glocal Research Centre (G2RC) focussed on Health Equity research, and she is a Senior Scientist at the Population Health Research Institute.
Dr. Anand is Professor of Medicine and Epidemiology at McMaster University and holds a Heart & Stroke endowed Chair recognizing her national impact. Dr. Anand’s research has revealed how sex, ethnicity, and social determinants influence cardiometabolic risk—shifting practice away from “one-size-fits-all” models toward equity-focused care. Her studies have set new standards for defining obesity, created validated ethnic-specific risk scoring systems, and led to the development and testing of community-based interventions in South Asian and Indigenous populations. Her findings have shaped clinical guidelines, policy frameworks, and global conversations on health equity. She has published over 500 peer-reviewed papers, led large-scale cohort studies (e.g., SHARE, EpiDREAM, CAHHM) and clinical trials (e.g., COMPASS, WAVE, SAHARA), and forged research partnerships with Indigenous communities grounded in ethical co-design. As a vascular medicine specialist, she also delivers care at Hamilton Health Sciences and mentors future clinician-scientists through Canada’s only Vascular Medicine Fellowship. Dr. Anand’s scholarship and leadership have been recognized by her election to both the Canadian Academy of Health Sciences (2019) and the Royal Society of Canada (2022). She currently leads McMaster’s new School of Global Health and Social Medicine—a platform for interdisciplinary solutions to health inequities in Canada and around the world. Her work exemplifies the power of science for impact—advancing discovery, implementation, and health system transformation with methodological rigor and cultural humility. Dr. Anand’s leadership continues to position Canada at the forefront of global health and health equity innovation.
Dr. Annie Genois is a dermatologist based in Montreal, Canada. She completed her dermatology residency at the Université de Montréal in 2018, after previously earning a law degree.
She is co-owner of Clinique de dermatologie Rosemont, where she practices general dermatology, caring for both adult and pediatric patients, and provides phototherapy. In collaboration with the Centre de recherche Saint-Louis, she is actively involved in clinical research as a principal investigator and sub-investigator in numerous clinical trials.
Her main clinical interests include inflammatory dermatoses and dermoscopy.
Dr. Shamir R. Mehta is the Douglas A. Holder Endowed Chair and Professor of Medicine at McMaster University. He is a Senior Scientist at the Population Health Research Institute, where he leads the Acute Coronary Syndrome and Interventional Cardiology Research Program. He is the Director of the Royal College Interventional Cardiology program at McMaster, where he practices coronary and structural interventional cardiology.
Dr. Mehta completed medical school and postgraduate internal medicine, general cardiology and interventional cardiology training at the University of Toronto. This was followed by a Master’s degree in Health Research Methodology at McMaster, where he was supported by a Canadian Institutes of Health Research New Investigator Award.
Dr. Mehta has published over 300 articles, editorials and book chapters and holds peer-review funding from the Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada. In addition, he has attracted industry-academic collaborative funding to support large-scale, multinational clinical trials. Dr. Mehta led the practice-changing PCI-CURE study a multinational trial establishing the benefit of early followed by long term treatment with a P2Y12 inhibitor in patients with ACS undergoing PCI. He was the principal investigator of the 25,000 patient CURRENT-OASIS 7 trial, one of the largest ACS randomized trials ever performed, evaluating aspirin and clopidogrel dosing after ACS. Dr. Mehta has also led major trials evaluating the role of invasive interventions in patients with ACS, including the RIVAL trial, an 8,000 patient trial evaluating the benefit of a radial artery versus femoral artery approach in patients with ACS and the 3,000 patient TIMACS trial evaluating early versus delayed invasive intervention in patients with ACS. He will present the primary results of the STRIVE trial evaluating intracoronary administration of low dose tissue plasminogen activator as an adjunct to primary PCI in patients with STEMI. Dr. Mehta was the principal investigator of the COMPLETE trial, a multinational trial of 4,041 patents evaluating a strategy of complete revascularization in patients with acute STEMI and multivessel disease. The COMPLETE trial was recognized by the editors of the New England Journal of Medicine as a Most Notable Article of 2019 and the American Heart Association recognized it as one of the top 10 advancements of that year. The COMPLETE trial results led to a Class 1A indication for complete revascularization with PCI for patients with STEMI in both the AHA/ACC ACS Guidelines as well as the ESC Guidelines.
Dr. Mehta is currently leading the COMPLETE-2 trial, a 5,100-patient multinational trial evaluating the role of physiology-guided versus angiography-guided PCI strategies to treat non-culprit lesions in patients with ACS and multivessel coronary artery disease, including a large-scale intracoronary imaging study using optical coherence tomography to predict cardiovascular events. He is also leading the development of novel pharmacologic strategies following ACS, including as an executive committee member of the Librexia ACS trial evaluating the novel Factor XIa inhibitor milvexian and the OCEAN(a) trial, evaluating targeted lowering of lipoprotein(a) after ACS or PCI with a novel small, interfering RNA.
Throughout his career, Dr. Mehta has received several awards and recognitions. In 2008, he was named one of Canada’s Top 40 Under 40. In 2022, he received the Canadian Cardiovascular Society Research Achievement Award and in 2024, Dr. Mehta was recognized with the Canadian Association of Interventional Cardiology Outstanding Achievement Award. In 2025, he was invited to deliver the Kenneth W.G. Brown Memorial Lecture, the signature event of the Division of Cardiology at the University of Toronto.
Dr. Siddhartha (Sid) Mengi joined the New Brunswick Heart Centre in 2025 as an interventional cardiologist specializing in coronary and structural heart interventions and serves as an Assistant Professor in the Department of Medicine at Dalhousie University.
He completed his medical degree with Honours from West China School of Medicine, Sichuan University, China, receiving four honors and the President’s Gold Medal for academic excellence. He obtained his MD from the University of Buckingham, United Kingdom, followed by general and interventional cardiology training in the National Health Service (NHS) England, earning a Certificate of Completion of Training (CCT) in Cardiology and Membership of the Royal College of Physicians of London, UK. He also holds European certification in General Cardiology and a Diploma in Clinical Cardiology from Johns Hopkins University, Baltimore, USA.
Dr. Mengi later completed advanced fellowship training in coronary and structural heart disease interventions at the Quebec Heart and Lung Institute (Institut universitaire de cardiologie et de pneumologie de Québec), Québec City. He is currently pursuing a PhD at Université Laval, Québec City, focusing on outcomes of transcatheter aortic valve implantation (TAVI) in heart failure.
An active researcher, he has co-authored numerous papers and research abstracts published in leading peer-reviewed cardiology and medical journals covering topics in interventional cardiology, structural therapies, heart failure and the latest developments in the field. He serves as a co-investigator in several multicentre registries and clinical trials involving percutaneous coronary intervention, TAVI and structural interventions, and has co-authored chapters in cardiology textbooks.
Dr. Mengi has performed more than 4,000 diagnostic and interventional cardiac procedures. His clinical expertise includes complex coronary procedures, intracoronary imaging (IVUS/OCT), TAVI, transcatheter mitral and tricuspid therapies and congenital procedures.
He is dedicated to advancing patient-centered cardiovascular care, research, and education in New Brunswick. He speaks French and English.
Dr. Marc S. Sabatine, MD, MPH is Chair of the TIMI Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital, and aProfessor of Medicine at Harvard Medical School. As Chair, Dr. Sabatine has led multiple large international clinical trials across a broad range of cardiovascular and metabolic therapeutics, resulting in FDA approval of new indications for medications and changes in practice guidelines. In addition to being a clinical trialist, Dr. Sabatine has been a pioneer in the multimarker approach to risk stratification, and has had multiple National Institutes of Health and American Heart Association grants supporting the application of proteomics and metabolomics for discovery of novel biomarkers. He also has a long-standing interest in pharmacogenetics and has made impactful observations on the ability to use genetics for personalized medicine. Dr. Sabatine has published extensively in these fields with many seminal papers in the New England Journal of Medicine, JAMA, and the Lancet. He has been one of the most highly cited researchers in medicine for many years running. He has mentored over 40 research fellows, many of whom have gone on to academic positions as physician-scientists around the world.
Dr. Harindra Wijeysundera is the Chief of the Schulich Heart Program, and Head of the Division of Cardiology, at Sunnybrook Health Sciences Center. In Toronto, Canada. He is as an interventional cardiologist and a senior scientist at Sunnybrook Research Institute as well as an adjunct senior scientist at ICES. He is a professor in the Department of Medicine and the Institute for Health Policy, Management and Evaluation (IHPME) at the University of Toronto. His clinical practice is focused on transcatheter aortic valve implantation (TAVI) and coronary chronic total occlusions.
He holds a Canada Research Chair in Structural Heart Disease Policy and Outcomes; hisresearch program focuses on health technology assessments in cardiovascular disease populated by population level administrative data for outcomes and costs.
He has been actively involved in health system leadership. From 2017-2020, he was the VP for Medical Devices at the Canadian Agency for Drugs and Technology in Health (CADTH). In 2022, he was appointed as the inaugural Provincial Cardiac Lead for CorHealth-Ontario Health.
Dr. Shelley Zieroth joined the Section of Cardiology as Director of Heart Function Clinics at St. Boniface Hospital in Winnipeg, Canada in July 2006. She is a Clinician-Scientist and Professor in the College of Medicine, Max Rady Faculty of Health Sciences, and cross-appointed to the Department of Pathophysiology and Pathology at the University of Manitoba. She holds the Heart & Stroke, St. Boniface Hospital Foundation, and Research Manitoba Chair in Women’s Clinical Heart Health Research.
Dr. Zieroth attended medical school at the University of Manitoba and went on to train in Internal Medicine and Cardiology at the same centre. She completed her Postdoctoral Clinical Fellowship, specializing in Advanced Heart Failure and Cardiac Transplant, at Toronto General Hospital.
Her research interests include heart failure and cardio-kidney-metabolic interactions. She holds leadership positions in international clinical trials and has enrolled many people in landmark clinical trials during her career. She has served as Associate Editor at JACC HF, European Journal of HF and the European Heart Journal.
She is a governor for ACC representing Canada and Past President of the Federation of Medical Women of Canada. She was recipient of the King Charles III Coronation medal for her work with the Federation in 2024. In 2026 she was named one of Canada’s Most Powerful Women: Top 100 Award Winner by WXN Media. Other leadership roles include co-Chair of the Canadian Heart Function Alliance Sex and Gender Working Group, Past President of the Canadian Heart Failure Society (CHFS) and she received the CHFS Annual Achievement Award in 2025. She has been a longstanding contributor and previous co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines and other international heart failure guidelines.